Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Codiak Biosciences Inc (CDAK)

Codiak Biosciences Inc (CDAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Codiak BioSciences Reports Second Quarter 2022 Financial Results and Operational Progress Globe Newswire - Thu Aug 4, 2022

– Reported platform-validating initial data from Phase 1 studies of exoSTING™ and exoIL-12™; plans to initiate Phase 2 studies for both programs in 1H 2023...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences Globe Newswire - Wed Aug 3, 2022

CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022 Globe Newswire - Mon Jul 11, 2022

CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the...

CDAK : 0.0570 (-55.98%)
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine Globe Newswire - Tue Jul 5, 2022

OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences...

CDAK : 0.0570 (-55.98%)
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTINGâ„¢ and exoIL-12â„¢ Globe Newswire - Thu Jun 30, 2022

– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest...

CDAK : 0.0570 (-55.98%)
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress Globe Newswire - Thu May 5, 2022

– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1...

CDAK : 0.0570 (-55.98%)
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer Globe Newswire - Mon May 2, 2022

– Experienced oncology drug developer with more than two decades advancing treatments for solid tumors and hematologic malignancies joins Codiak leadership...

CDAK : 0.0570 (-55.98%)
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine Globe Newswire - Wed Apr 20, 2022

– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak...

CDAK : 0.0570 (-55.98%)
Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform Business Wire - Tue Apr 19, 2022

Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing....

AXLA : 0.4009 (-8.89%)
CDAK : 0.0570 (-55.98%)
DNLI : 30.91 (-0.45%)
EVLO : 0.0001 (unch)
FHTX : 9.99 (+3.31%)
MRNA : 65.69 (-3.43%)
OMGA : 1.3700 (-3.52%)
RUBY : 0.0570 (+2.70%)
SANA : 4.25 (-8.01%)
MCRB : 1.1300 (+7.62%)
SGTX : 22.47 (-2.56%)
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells Globe Newswire - Fri Apr 8, 2022

– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription...

CDAK : 0.0570 (-55.98%)

Barchart Exclusives

Does Your Portfolio Have Room for a 79% 5-Year Track Record ETF? Barchart - Sun Sep 22, 5:16PM CDT
Equity investors often overlook market seasonality. Unfortunately, seasonality is usually tied to future markets. However, there are instances where the seasonality of commodities can enhance an Exchange-Traded Fund (ETF). Two significant commodities are entering a seasonal buy that will impact an outperforming homebuilder ETF. The Federal Reserve (FED) appears ready to begin a new cycle of lower rates, which may catalyze this ETF seasonal pattern. Does Your Portfolio Have Room for a 79% 5-Year Track Record ETF? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot